Extended-Release Metformin Combo Drug Given the Green Light


By: Daniel Trecroci

Glumetza, a once-daily extended-release formulation of metformin hydrochloride, was granted FDA approval in June 2005 for the treatment of type 2 diabetes.

According to Biovail, the drug’s manufacturer, Glumetza “may offer potential advantages such as less frequent dosing and proven effectiveness in combination with other diabetes drugs.” In addition, they say that Glumetza offers “excellent tolerability that allows physicians to more quickly administer a high enough dose to provide [blood glucose] control without significantly increasing the incidence of nausea, diarrhea and other side effects that are sometimes caused by metformin products.”

Glumetza is not recommend for people with kidney problems, heart failure that is treated with medicine, or diabetic ketoacidosis. The most common side effects of Glumetza include diarrhea, nausea and upset stomach. Glumetza can also cause lactic acidosis.

Source: Biovail Corp.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.